Unknown

Dataset Information

0

TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion.


ABSTRACT: Immune checkpoint inhibitors such as anti-CTLA-4 antibody are widely accepted therapeutic options for many cancers, but there is still a considerable gap in achieving their full potential. We explored the potential of activating the innate and adaptive immune pathways together to improve tumor reduction and survival outcomes. We treated a mouse model of melanoma with intratumoral injections of Toll-like receptor 1/2 (TLR1/2) ligand Pam3CSK4 plus i.p. injections of anti-CTLA-4 antibody. This combination treatment enhanced antitumor immune responses both qualitatively and quantitatively over anti-CTLA-4 alone, and its efficacy depended on CD4 T cells, CD8 T cells, Fc? receptor IV, and macrophages. Interestingly, our results suggest a unique mechanism by which TLR1/2 ligand increased Fc? receptor IV expression on macrophages, leading to antibody-dependent macrophage-mediated depletion of regulatory T cells in the tumor microenvironment and increasing efficacy of anti-CTLA-4 antibody in the combination treatment. This mechanism could be harnessed to modulate the clinical outcome of anti-CTLA-4 antibodies and possibly other antibody-based immunotherapies.

SUBMITTER: Sharma N 

PROVIDER: S-EPMC6534983 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion.

Sharma Naveen N   Vacher Jean J   Allison James P JP  

Proceedings of the National Academy of Sciences of the United States of America 20190510 21


Immune checkpoint inhibitors such as anti-CTLA-4 antibody are widely accepted therapeutic options for many cancers, but there is still a considerable gap in achieving their full potential. We explored the potential of activating the innate and adaptive immune pathways together to improve tumor reduction and survival outcomes. We treated a mouse model of melanoma with intratumoral injections of Toll-like receptor 1/2 (TLR1/2) ligand Pam3CSK4 plus i.p. injections of anti-CTLA-4 antibody. This comb  ...[more]

Similar Datasets

| S-EPMC5739581 | biostudies-literature
| S-EPMC7821912 | biostudies-literature
| S-EPMC4375105 | biostudies-literature
| S-EPMC11344484 | biostudies-literature
| S-EPMC6857638 | biostudies-literature
| S-EPMC3085474 | biostudies-literature
| S-EPMC8115697 | biostudies-literature
| S-EPMC9667294 | biostudies-literature
| S-EPMC5093041 | biostudies-literature
| S-EPMC5897134 | biostudies-literature